Lecia V Sequist
机构: Professor of Medicine, Harvard Medical School and Massachusetts General Hospital
每年引用次数
引用次数
引用: 78,900
H-指数: 113
I10-指数 : 308
出版物: 600
Isolation and Molecular Characterization of Circulating Melanoma Cells
Xi Luo , Devarati Mitra , Ryan J. Sullivan , Ben S. Wittner
Cell Reports 7 ( 3) 645 -653
69
2014
SECTION J
PIERRE P MASSION , LECIA V SEQUIST , WILLIAM PAO
Searching the Web
Christian BERG , Jacob Stordal CHRISTIANSEN , Henrik Laurberg PEDERSEN
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Lecia V. Sequist , Joel W. Neal
Clinical advances in hematology & oncology 8 ( 2) 119 -126
15
2010
Adjuvant molecularly targeted therapy—epidermal growth factor tyrosine kinase inhibition and beyond
Lecia V. Sequist , Joel W. Neal
Translational lung cancer research 2 ( 5) 411 -414
1
2013
A New Era of Protein-Based Assays for Cancer Early Detection.
Lecia V. Sequist , Steven J. Skates , Wilhelm Haas
Journal of Thoracic Oncology 16 ( 2) 191 -193
2021
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer
Mark G. Kris , Lecia V. Sequist , Deepa Rangachari , Jamie E. Chaft
JCO Precision Oncology ( 5) 325 -332
2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
Lecia V. Sequist , Subba R. Digumarthy , Jennifer S. Temel , Jochen K. Lennerz
Clinical Cancer Research 27 ( 10) 2899 -2909
2021
Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.
Anna F. Farago , Zofia Piotrowska , Lecia V. Sequist
Journal of Clinical Oncology 35 ( 26) 2987 -2988
8
2017
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott Gettinger , Leora Horn , David Jackman , David Spigel
Journal of Clinical Oncology 36 ( 17) 1675 -1684
581
2018
Abstract IA09: Single cell RNA-sequencing of circulating tumor cells
David T. Miyamoto , Yu Zheng , Ben S. Wittner , Richard J. Lee
Clinical Cancer Research 22
2016
The challenges of repeat biopsies at acquired resistance to EGFR TKIs.
Meghan Campo , Zofia Piotrowska , Alona Muzikansky , Coleen Rizzo
Journal of Clinical Oncology 34
1
2016
Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
Jacob J. Chabon , Andrew Simmons , Aaron M. Newman , Alexander F. Lovejoy
Journal of Clinical Oncology 34 9000 -9000
4
2016
Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.
Shirish M. Gadgeel , James Stevenson , Corey J. Langer , Leena Gandhi
Journal of Clinical Oncology 34 9016 -9016
92
2016
Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.
Matthew A. Gubens , Lecia V. Sequist , James Stevenson , Steven Francis Powell
Journal of Clinical Oncology 34 9027 -9027
25
2016
Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.
Heather A. Wakelee , Shirish M. Gadgeel , Jonathan Wade Goldman , Karen L. Reckamp
Journal of Clinical Oncology 34 9001 -9001
24
2016
Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.
Daniel Shao-Weng Tan , James Chih-Hsin Yang , Natasha B. Leighl , Gregory J. Riely
Journal of Clinical Oncology 34 9044 -9044
34
2016
Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).
Jonathan Wade Goldman , Jean-Charles Soria , Heather A. Wakelee , D. Ross Camidge
Journal of Clinical Oncology 34 9045 -9045
9
2016
Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib.
Justin F. Gainor , Luc Friboulet , Satoshi Yoda , Leila Dardaei Alghalandis
Journal of Clinical Oncology 34 ( 15_suppl) 9072 -9072
11
2016
General medical oncologists assessment and use of targeted treatment for patients (pts) with metastatic nonsquamous non-small cell lung cancer (nsqNSCLC).
Neil Love , Geoffrey R. Oxnard , Lynette M. Sholl , Lecia V. Sequist
Journal of Clinical Oncology 35
2017